Prospect News: News for K-V Pharmaceutical Co.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with K > Issuers starting with K, DD only > All stories on K-V Pharmaceutical Co. > Stories on K-V Pharmaceutical Co., DD only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

K-V Pharmaceutical Co.

9/16/2013	BKDD	K-V Pharmaceutical exits bankruptcy with $375 million recapitalization
9/11/2013	DD	K-V Pharmaceutical obtains OK of settlement with Florida, Ven-a-Care
8/29/2013	DD	K-V Pharmaceutical's sixth amended joint reorganization plan confirmed
8/16/2013	DD	K-V Pharmaceutical records $4.53 million of operating income for July
8/15/2013	DD	K-V Pharmaceutical obtains court approval of Gedeon Richter settlement
8/14/2013	DD	K-V Pharmaceutical eyes exclusivity extension ahead of plan hearing
8/13/2013	DD	K-V Pharmaceutical, Florida and Ven-a-Care settle lawsuit and claim
7/24/2013	DD	K-V Pharmaceutical, Gedeon ink settlement to resolve agreement issues
7/17/2013	DD	K-V Pharmaceutical disclosure approved; plan hearing set for Aug. 28
7/16/2013	DD	K-V Pharmaceutical reports $2.3 million of operating income for June
7/5/2013	DD	K-V Pharmaceutical noteholders seek to subordinate convertible notes
6/20/2013	DD	K-V Pharmaceutical's $3 million Texas Medicaid fraud settlement OK'd
6/17/2013	DD	K-V Pharmaceutical reports $1.6 million of operating income for May
6/7/2013	DD	K-V Pharmaceutical replacement financing, exclusivity extension OK'd
6/6/2013	DD	K-V Pharmaceutical convertible noteholder group supports investor plan
5/30/2013	DD	K-V Pharmaceutical delays hearing on financing, exclusivity extension
5/28/2013	DD	K-V Pharmaceutical reaches $3 million Texas Medicaid fraud settlement
5/15/2013	DD	K-V Pharmaceutical eyes exclusivity extension; proposal selection near
5/15/2013	DD	K-V Pharmaceutical eyes exclusivity extension; proposal selection near
5/15/2013	DD	K-V Pharmaceutical reports $1.57 million of operating income for April
5/8/2013	DD	K-V Pharmaceutical lenders, noteholders ask to delay financing hearing
5/3/2013	BKDD	K-V Pharmaceutical gets alternative plan proposal, DIP loan commitment
4/22/2013	DD	K-V Pharmaceutical files second amended plan; statement hearing May 1
4/16/2013	DD	K-V Pharmaceutical reports operating income of $1.76 million in March
4/12/2013	DD	K-V Pharmaceutical creditors preparing equity financing commitment
3/19/2013	DD	K-V Pharmaceutical submits amended plan; statement hearing April 23
3/15/2013	DD	K-V Pharmaceutical operating income rises to $572,000 in February
2/28/2013	DD	K-V Pharmaceutical creditors ask court to adjourn confirmation hearing
2/15/2013	DD	K-V Pharmaceutical operating income declines to $127,000 in January
2/11/2013	DD	Court: K-V Pharmaceutical noteholders do not have interest in Makena
2/5/2013	DD	K-V Pharmaceutical secures exclusivity extension to negotiate plan
1/16/2013	DD	K-V Pharmaceutical sees $1.46 million of operating income in December
1/10/2013	DD	K-V Pharmaceutical seeks 120-day extension of plan exclusive periods
1/8/2013	DD	K-V Pharmaceutical creditors claim noteholders have no Makena interest
1/8/2013	DD	K-V Pharmaceutical submits plan based on senior noteholder agreement
12/31/2012	DD	K-V Pharmaceutical wins approval of DIP financing, Hologic settlement
12/19/2012	DD	K-V Pharmaceutical's creditors committee objects to proposed $60 million Hologic, Cytyc settlement
12/18/2012	DD	K-V Pharmaceutical records $242,000 of operating income for November
12/13/2012	DD	K-V Pharmaceutical, senior noteholders agree to Chapter 11 plan terms
12/12/2012	DD	K-V Pharmaceutical requests approval of $85 million in DIP financing
12/12/2012	DD	K-V Pharmaceutical to file reorganization plan for court confirmation
12/5/2012	DD	K-V Pharmaceutical seeks approval of $60 million Hologic settlement
11/27/2012	DD	K-V Pharmaceutical trustee raises questions regarding notes indenture
11/16/2012	DD	K-V Pharmaceutical gets shorter exclusivity extension than requested
11/15/2012	DD	K-V Pharmaceutical records $624,000 of operating income for October
11/7/2012	DD	K-V Pharmaceutical creditor Hologic objects to exclusivity extension
10/26/2012	DD	K-V Pharmaceutical seeks 90-day extension of exclusive plan periods
10/19/2012	DD	K-V Pharmaceutical cash collateral extended to Nov. 21 from Oct. 18
10/16/2012	DD	K-V Pharmaceutical operating loss narrows to $4 million in September
9/26/2012	DD	K-V Pharmaceutical records $4.09 million operating loss for August
9/14/2012	DD	K-V Pharmaceutical granted final approval of use of cash collateral
8/24/2012	DD	K-V Pharmaceutical creditors committee object to cash collateral order
8/13/2012	DD	K-V Pharmaceutical official unsecured creditors committee appointed
8/10/2012	DD	Prospect News reports two new defaults for week of July 26 to Aug. 8
8/9/2012	DD	K-V Pharmaceutical receives court approval for use of cash collateral
8/8/2012	DD	K-V Pharmaceutical seeks approval of interim access to cash collateral
8/8/2012	DD	K-V class A and B common shares trade on OTCQB after NYSE suspension
8/6/2012	CVDDPV	K-V Pharmaceutical in bankruptcy to restructure financial obligations
7/2/2012	DD	Market Commentary: Distressed debt action muted due to holiday; ATP heralds natural gas find, bonds hold steady
6/22/2012	DD	Market Commentary: KV Pharma takes tumble as company struggles with Makena drug; ATP debt closes steady to softer
5/4/2011	DD	Market Commentary: Harrah's gains on loan change news; KV Pharma trading volatile; Catalyst slips, NewPage mixed
2/14/2011	BKDD	K-V reaches agreement on amendment to facility size and structure
1/12/2011	DD	Market Commentary: Distressed market stronger, still muted on new issues; Catalyst Paper jumps on redemption news
7/24/2009	CVDD	K-V Pharmaceutical needs more capital; going concern status in doubt

©2026 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.